Showing posts with label biosimilars. Show all posts
Showing posts with label biosimilars. Show all posts

Tuesday, April 14, 2009

Congress pushes for biosimilars pathway

March 2009 saw the US Congress turn its attention to the issue of creating a regulatory pathway for biosimilars (see p. 11). However, two competing visions have emerged, both originating in the House of Representatives, and predictably, one is favoured by the generics industry whilst the other is favoured by the biotech industry. First out of the blocks was a bipartisan bill, H.R. 1427, Promoting Innovation and Access to Life-Saving Medicine Act, introduced by Henry Waxman, Nathan Deal, Frank Pallone and Jo Ann Emerson. With Mr Waxman‟s name on the bill, it is no surprise that the generic industry favour this bill. However, within days, a second bill, H.R. 1548, the Pathway for Biosimilars Act, was introduced, again by a bipartisan group of representatives, including Anna Eshoo, Jay Inslee and Joe Barton. This bill has won the approval of BIO.

Both bills are broadly similar, basically attempting to set out a regulatory pathway on the same lines as the Hatch-Waxman Act. However, there is one essential difference between the two: H.R. 1427 gives original biologics five years of exclusivity, with certain modifications of existing drugs getting three years. These periods can be extended for up to a year. Meanwhile, H.R. 1548 provides up to 14 ½ years of data exclusivity for new biologics. It is clear why the generics industry would favour one bill whilst the biologic industry would favour the other. This also suggests the two competing bills are the result of lobbying by the various industry interests. This is backed up by the fact that Representative Inslee represents a Seattle-area district with a strong biotech sector. In addition, Mr Inslee also serves on the House Energy and Commerce Committee, as does Ms Eshoo and Mr Barton, who is the ranking member of the committee. However, the committee is chaired by Mr Waxman, who can also call on support from his cosponsors, Mr Pallone and Mr Deal, so clearly the two bills will be the subject of considerable debate. How the two bills fare in the committee stage will be an interesting battle of wills.

Outside of Congress, the various proponents and opponents of the two bills have shown differing approaches in how they are trying to sell their arguments. BIO has said that it has safety concerns over H.R. 1427, whilst applauds the alternative bill, H.R. 1548, for being safer. However, it seems likely that BIO‟s more immediate concern is over the length of data protection, which is a legitimate concern for the industry, but not necessarily one that will fly with the general public. BIO also expresses concern that H.R. 1427 would jeopardise biotech jobs, noting that the industry supports 7.5 million jobs in America, with these jobs generally being highly paid, and therefore good contributors to the economy. Conversely, the GPhA also uses the economy angle in its support of H.R. 1427, arguing that the bill would help the economy by strengthening healthcare whilst reducing costs to the public. The GPhA adds that the bill is supported by consumer, business and labour organisations. Both sides recognise that a regulatory pathway for biosimilars is inevitable. However, what shape that legislation will ultimately take is less clear, and will seemingly depend on political skills and an ability to convince public opinion.

Ian Platts - Editor, World Generic Markets

Friday, March 13, 2009

Biosimilars in the US a step closer?

President Obama has released his budget proposals, including those for the Department of Health and Human Services. The proposal would provide US$76.8 billion to the HHS, whilst the FDA is requesting nearly US$2.4 billion, an increase of 5.7% over the budget that the agency received for the current fiscal year. Not surprisingly, much of the focus on the healthcare aspects of the budget have been on the headline-grabbing issues, such as healthcare reform and the doubling of funding for cancer research. However, another aspect of the budget which deserves attention is its proposal to establish a regulatory pathway to approve generic biologics.

This has long been a thorny issue for the United States with the result that the country has lagged behind the European Union, where a basic approval pathway for biosimilars has been hammered out. Progress on the issue in the US has never been forthcoming, with the opposing sides of the argument clashing on all issues surrounding biosimilars, from their safety and efficacy to the length of data exclusivity periods for biologic products. Whilst none of the parties may have actually said that they do not want biosimilars allowed, the efforts to torpedo any attempt to create a pathway have spoken volumes.

With the new budget proposal specifically seeking to create a regulatory pathway, the question of whether this logjam can be broken has to be asked. President Obama has a focus on healthcare issues in general, with an intention to make the system more cost-effective and widen coverage for more Americans. Mr Obama’s nomination, albeit a second attempt after Tom Daschle, of Kathleen Sebelius, currently the Governor of Kansas, to the post of Secretary of Health and Human Services can be seen to underscore a determination to make changes. Ms Sebelius is a popular Democratic governor in a Republican-dominated state, a position which suggests that bipartisan working has been an essential element of Ms Sebelius’ job, and in turn suggests the same approach will be used should she become the head of the HHS. Thus the job would be taken by somebody with experience in successfully negotiating between staunchly opposed interests, which would surely be essential in any effort to produce a working regulatory pathway for biosimilars. Prior to this nomination, Henry Waxman was voted by the Democratic Caucus to become Chairman of the Committee on Energy and Commerce, which will have oversight on healthcare issues. Mr Waxman has long been known to support establishing a regulatory pathway for biosimilars, and his appointment must surely up the ante.

However, this is an issue which has long confounded its advocates, and whilst the political landscape may have moved to more fertile grounds for creating a pathway, the arguments against it have not been diminished. The issue of biosimilar safety will continue to be a problem, particularly for a litigious nation; entrenched arguments over data exclusivity will not now go away, and the savings through generic biologics will still be pitted against costs to American innovative companies and their employees. The push to create a pathway may have taken one step forward, but there still remains plenty of opportunity for its opponents to claw two steps back.

Ian Platts - Editor, World Generic Markets

Friday, May 2, 2008

Biosimilars Business Review, April 2008

Europe saw another positive move in February 2008, when the EMEA recommended approval for three GCSF biosimilars. Marketing can begin once the European Commission issues final approval in April 2008. This will mark Teva’s first biosimilar approval in the EU; the company is developing its biosimilar activities apace, as demonstrated by the recently-announced purchase of CoGenesys.

An indication of attitudes to biosimilars in the European marketplace was given by the publication of a report by a UK parliamentary panel into the subject in January. It indicated a general lack of awareness of biosimilars within the Department of Health and the wider health service, and came down strongly against the allowance of substitution. Shortly afterwards, the MHRA issued a brief guidance stating that it is ‘good practice’ to prescribe by brand name only. The parliamentary panel issued a number of other recommendations, none of which will be particularly welcome to the biosimilar industry.

In the USA, the wind has changed, for the time being at least. The running is now being made by the originator industry, which has decided its best interests are served by passing legislation this year rather than delaying; the political environment may be less favourable in 2009. Hence the specific mention of biosimilar regulations in President Bush’s budget request, and the public support given by BIO to the new Barton-Eshoo bill in the House. In contrast, the biosimilar industry has become more cautious, calculating that it can get a better bill after the November 2008 elections. With Congress finely balanced and a real lack of consensus over the issue of market exclusivity, it would be brave indeed to predict the creation of a pathway this year.

Andrew Crofts – Editor, Biosimilars Business Review

Europe gets nervous over biosimilar rules

The United Kingdom is currently debating new biosimilar rules, as part of a movement amongst European countries to limit how centralised biosimilar approvals are prescribed. Recommendations put forward include prescription of biosimilars by brand names only, an urgent ban on substitution "until effective safeguards can be relied on", and applying the Medicine and Healthcare Regulatory Authority’s black triangle symbol "be applied to all biosimilar drugs and that, at two-year or other periodic review, that symbol should remain unless the safety evidence is clear that it can be removed".

Changes to prescription rules follow advice from the EMEA in June 2007 that biosimilars cannot be considered identical to their biological reference products. However, while the agency can issue advice, prescription policies are set at a national level; this has led to European countries diluting the strength of the original centralised rules, mainly due to safety fears caused by biosimilar complexity and subtle differences from originator products. According to the European Generic medicines Association (EGA), fifteen countries across Europe have brought in new rules to prevent the automatic substitution of biological medicines by biosimilars, including France, Spain, the Netherlands and Norway.

This contrasts with the approach in the United States, which has not even got so far as creating a biosimilar pathway. However, events in Europe are an indication that the US may also run into difficulties with biosimilar prescription rules following the approval of its own biosimilar legislation. This itself is currently on hold, as a suitable compromise between originator and biosimilar firms has not yet been reached. Interestingly, the forces pushing for legislation sooner have recently been reversed, with the branded industry keen to get a bill through Congress before President Bush leaves office.

The US and European biosimilar agendas are notably different at present, united only by lingering uncertainties remaining in both. This is likely to remain the case in the short term, due to a number of factors such as safety fears and the high costs of producing biological drugs in any form. The boom year for the biosimilar industry will not arrive until 2012 at the earliest, when a much higher proportion of biological drugs start to come off patent. At that time, the financial incentives of promoting biosimilars will be hard for governments to ignore, while experience of biosimilars should lead to more uniformity in safety rules.

Jonathan Way - Editor, World Generic Markets